Very low PSA concentrations and deletions of the KLK3 gene

Clinical Chemistry

Volumn 59, Issue 1, 2013, Pages 234-244

  Rodriguez, Santiago ^a   Al Ghamdi, Osama A ^a   Burrows, Kimberley ^a   Guthrie, Philip A I ^a   Athene Lane, J ^a   Davis, Michael ^a   Marsden, Gemma ^b   Alharbi, Khalid K ^c   Cox, Angela ^d   Hamdy, Freddie C ^b   Neal, David E ^e   Donovan, Jenny L ^a   Day, Ian N M ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c KING SAUD UNIVERSITY   (Saudi Arabia)

^d UNIVERSITY OF SHEFFIELD   (United Kingdom)

^e UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

KALLIKREIN; KALLIKREIN RELATED PEPTIDASE 3; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CODON; CONTROLLED STUDY; EXON; FRAMESHIFT MUTATION; GENE DELETION; GENE DOSAGE; GENE DUPLICATION; GENE EXPRESSION; GENETIC ANALYSIS; GENETIC VARIABILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; PROMOTER REGION; PROSTATE CANCER;

EXONS; GENE DELETION; HUMANS; KALLIKREINS; MALE; MUTATION; POLYMERASE CHAIN REACTION; PROSTATE-SPECIFIC ANTIGEN;

EID: 84872025018     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2012.192815     Document Type: Article

References (27)

1. Lilja H, Ulmert D, Vickers AJ. Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. Nat Rev Cancer 2008;8:268-78.
2. Oesterling JE, Jacobsen SJ, Chute CG, Guess HA, Girman CJ, Panser LA, Lieber MM. Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. JAMA 1993;270:860-4.
3. Yan Y. Intraindividual variation of prostate specific antigen measurement and implications for early detection of prostate carcinoma. Cancer 2001;92:776-80.
4. Lawrence MG, Lai J, Clements JA. Kallikreins on steroids: structure, function, and hormonal regulation of prostate-specific antigen and the extended kallikrein locus. Endocr Rev 2010;31:407-46.
5. Cramer SD, Chang BL, Rao A, Hawkins GA, Zheng SL, Wade WN, et al. Association between genetic polymorphisms in the prostate-specific antigen gene promoter and serum prostate-specific antigen levels. J Natl Cancer Inst 2003;95:1044-53.
6. Cramer SD, Sun J, Zheng SL, Xu J, Peehl DM. Association of prostate-specific antigen promoter genotype with clinical and histopathologic features of prostate cancer. Cancer Epidemiol Biomarkers Prev 2008;17:2451-7.
7. Lai J, Kedda MA, Hinze K, Smith RL, Yaxley J, Spurdle AB, et al. PSA/KLK3 AREI promoter polymorphism alters androgen receptor binding and is associated with prostate cancer susceptibility. Carcinogenesis 2007;28:1032-9.
8. Eeles RA, Kote-Jarai Z, Giles GG, Olama AA, Guy M, Jugurnauth SK, et al. Multiple newly identified loci associated with prostate cancer susceptibility. Nat Genet 2008;40:316-21.
9. Ahn J, Berndt SI, Wacholder S, Kraft P, Kibel AS, Yeager M, et al. Variation in KLK genes, prostate-specific antigen and risk of prostate cancer. Nat Genet 2008;40:1032-4.
10. Gudmundsson J, Besenbacher S, Sulem P, Gudbjartsson DF, Olafsson I, Arinbjarnarson S, et al. Genetic correction of PSA values using sequence variants associated with PSA levels. Sci Transl Med 2010;2:62ra92.
11. Kote-Jarai Z, Amin Al Olama A, Leongamornlert DA, Tymrakiewicz M, Saunders J, Guy M, et al. Identification of a novel prostate cancer susceptibility variant in the KLK3 gene transcript. Hum Genet 2011;129:687-94.
12. Parikh H, Deng Z, Yeager M, Boland J, Matthews C, Jia J, et al. A comprehensive resequence analysis of the KLK15-KLK3-KLK2 locus on chromosome 19q13.33. Hum Genet 2010;127:91-9.
13. Klein RJ, Hallden C, Cronin AM, Ploner A, Wiklund F, Bjartell AS, et al. Blood biomarker levels to aid discovery of cancer-related single-nucleotide polymorphisms: kallikreins and prostate cancer. Cancer Prev Res (Phila) 2010;3:611-9.
14. Donovan J, Hamdy F, Neal D, Peters T, Oliver S, Brindle L, et al. Prostate Testing for Cancer and Treatment (ProtecT) feasibility study. Health Technol Assess 2003;7:1-88.
15. Collin SM, Metcalfe C, Zuccolo L, Lewis SJ, Chen L, Cox A, et al. Association of folate-pathway gene polymorphisms with the risk of prostate cancer: a population-based nested case-control study, systematic review, and meta-analysis. Cancer Epidemiol Biomarkers Prev 2009;18:2528-39.
16. Chen L, Davey SG, Evans DM, Cox A, Lawlor DA, Donovan J, et al. Genetic variants in the vitamin D receptor are associated with advanced prostate cancer at diagnosis: findings from the Prostate Testing for Cancer and Treatment study and a systematic review. Cancer Epidemiol Biomarkers Prev 2009;18:2874-81.
17. Lamph SA, Sturgeon CM, White PAE, Price CP, Halloran SP. Evaluation report: total PSA assays. Centre for Evidence-based Purchasing (CEP), Purchasing and Supply Agency, National Health System. February 2009. CEP09004.
18. Guthrie PA, Gaunt TR, Abdollahi MR, Rodriguez S, Lawlor DA, Smith GD, Day IN. Amplification ratio control system for copy number variation genotyping. Nucleic Acids Res 2011;39:e54.
19. Atalay AC, Karaman MI, Guney S, Dalkilic A, Muslumanoglu AY, Ergenekon E. Age-specific PSA reference ranges in a group of non-urologic patients. Int Urol Nephrol 1998;30:587-91.
20. David A, Mabjeesh N, Azar I, Biton S, Engel S, Bernstein J, et al. Unusual alternative splicing within the human kallikrein genes KLK2 and KLK3 gives rise to novel prostate-specific proteins. J Biol Chem 2002;277:18084-90.
21. Michael IP, Kurlender L, Memari N, Yousef GM, Du D, Grass L, et al. Intron retention: a common splicing event within the human kallikrein gene family. Clin Chem 2005;51:506-15.
22. Kralovicova J, Gaunt TR, Rodriguez S, Wood PJ, Day IN, Vorechovsky I. Variants in the human insulin gene that affect pre-mRNA splicing: Is -23HphI a functional single nucleotide polymorphism at IDDM2? Diabetes 2006;55:260-4.
23. Rodriguez S, Gaunt TR, Vorechovsky I, Kralovicova J, Wood PJ, Day IN. Comment on: Marchand and Polychronakos (2007) evaluation of polymorphic splicing in the mechanism of the association of the insulin gene with diabetes: Diabetes 2007;56:709-713. Diabetes;56:e16.
24. Day IN, Rodriguez S, Kralovicova J, Wood PJ, Vorechovsky I, Gaunt TR. Questioning INS VNTR role in obesity and diabetes: subclasses tag IGF2-INS-TH haplotypes; and -23HphI as a STEP (splicing and translational efficiency polymorphism). Physiol Genomics 2006;28:113.
25. Raistrick CA, Day IN, Gaunt TR. Genome-wide data-mining of candidate human splice translational efficiency polymorphisms (STEPs) and an online database. PLoS One 2010;5:e13340.
26. McGee TL, Devoto M, Ott J, Berson EL, Dryja TP. Evidence that the penetrance of mutations at the RP11 locus causing dominant retinitis pigmentosa is influenced by a gene linked to the homologous RP11 allele. Am J Hum Genet 1997;61:1059-66.
27. De AG, Rittenhouse HG, Mikolajczyk SD, Blair SL, Semjonow A. Twenty years of PSA: from prostate antigen to tumor marker. Rev Urol 2007;9:113-23.